Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Medulloblastoma × Cytarabine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Leukemia, Myeloid, Acute 177 Leukemia 98 Lymphoma 82 Precursor Cell Lymphoblastic Leukemia-Lymphoma 75 Burkitt Lymphoma 46 Myelodysplastic Syndromes 43 Lymphoma, Mantle-Cell 43 Lymphoma, Large B-Cell, Diffuse 41 Lymphoma, Non-Hodgkin 40 Leukemia, Monocytic, Acute 29 Leukemia, Myelomonocytic, Acute 28 Lymphoma, Follicular 26 Leukemia, Erythroblastic, Acute 24 Leukemia, Megakaryoblastic, Acute 23 Recurrence 22 Lymphoma, Large-Cell, Immunoblastic 22 Congenital Abnormalities 22 Hodgkin Disease 18 Leukemia, Lymphocytic, Chronic, B-Cell 17 Leukemia, Myelomonocytic, Chronic 16 Blast Crisis 15 Anemia, Refractory, with Excess of Blasts 14 Lymphoma, B-Cell, Marginal Zone 13 Myeloproliferative Disorders 11 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 11 Dendritic Cell Sarcoma, Interdigitating 11 Multiple Myeloma 10 Leukemia, Myeloid, Chronic-Phase 10 Leukemia, Myeloid, Accelerated Phase 10 Leukemia, Biphenotypic, Acute 10

Interventions

Cyclophosphamide 16 Etoposide 11 Temozolomide 10 Magnetic Resonance Spectroscopy 8 Filgrastim 8 Cisplatin 8 Vincristine 7 Radiotherapy 7 Irinotecan 7 Carboplatin 7 X-Rays 6 Phantoms, Imaging 6 Topotecan 5 Specimen Handling 5 Peripheral Blood Stem Cell Transplantation 5 Nuclear Medicine Department, Hospital 5 Thiotepa 4 Biopsy 4 Bevacizumab 4 sargramostim 3 palbociclib 3 olaparib 3 Methotrexate 3 Chemotherapy, Adjuvant 3 ulixertinib 2 tipifarnib 2 tazemetostat 2 sonidegib 2 selpercatinib 2 larotrectinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01356290 2026-02-23

MEMMAT

Medical University of Vienna

Phase 2 Recruiting

Ependymoma, Medulloblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡